{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/urinary-tract-infection-children/prescribing-information/trimethoprim/","result":{"pageContext":{"chapter":{"id":"49e814b6-1bc7-5c87-91e7-ea6edc49413f","slug":"trimethoprim","fullItemName":"Trimethoprim","depth":2,"htmlHeader":"<!-- begin field 70de91f4-eaab-4755-95ec-aeaecb01d9f8 --><h2>Trimethoprim</h2><!-- end field 70de91f4-eaab-4755-95ec-aeaecb01d9f8 -->","summary":"","htmlStringContent":"<!-- begin item e618ace1-5118-40b5-8d85-71bb28ff0e99 --><!-- end item e618ace1-5118-40b5-8d85-71bb28ff0e99 -->","topic":{"id":"991f627d-8926-57b4-aaf8-67af4fd5db9d","topicId":"510a3aa0-27ac-462a-a52b-fe6491d08ab0","topicName":"Urinary tract infection - children","slug":"urinary-tract-infection-children","lastRevised":"Last revised in February 2019","chapters":[{"id":"d1ecfd05-b7d6-5f26-958b-08cbc3d78492","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5867e1c1-3817-541e-8b04-bef811c2f6c4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"79d4f794-da69-53db-a658-5ce7c959f692","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"2f77533f-9993-5dbe-aec4-d0ee486a2559","slug":"changes","fullItemName":"Changes"},{"id":"79054143-84a5-50b1-8bcd-34d7ea4ff7da","slug":"update","fullItemName":"Update"}]},{"id":"26055421-3310-5e60-9152-68faccc1b450","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2e0770ba-47ca-5e33-8ed4-cc1f3f27b080","slug":"goals","fullItemName":"Goals"},{"id":"9b22c988-34f6-555d-9dc3-8ab3bb093e3a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"fe1b7a61-e520-56e2-be30-8608881cdb7f","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"2b6a45d0-fdcd-5821-864d-63a74db81d6a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e6f051e1-15a3-55a3-be65-2a623b2dae1c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8b4bab45-57e8-59b8-bd66-9036dc2fc571","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"dd9ffb6c-bd87-54d5-8c87-1e080e01ea4b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"1136e250-9882-5b2e-a75c-91e52993494f","slug":"definition","fullItemName":"Definition"},{"id":"45b0687c-19a3-5dc0-a5aa-e56c1e8d1061","slug":"causal-organisms","fullItemName":"Causal organisms"},{"id":"003daae9-bb06-5297-8ac5-cabcf10e7968","slug":"prevalence","fullItemName":"Prevalence"},{"id":"750a5b3e-7655-5653-bd66-cbf33a4daffe","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"2d85acf8-d02b-5815-bb49-4c5f17b8678f","slug":"prognosis","fullItemName":"Prognosis"},{"id":"9f9d006d-bcda-5469-81d7-d2c3123c99d4","slug":"complications","fullItemName":"Complications"}]},{"id":"0bd6000e-bd4c-5f90-a711-bd23da73865d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8f91b779-7c82-5647-b2f7-d8c90726d303","slug":"suspecting-a-urinary-tract-infection","fullItemName":"Suspecting a urinary tract infection"},{"id":"5e82d0e6-4bfb-58c7-955f-7d2bc44d7ff6","slug":"diagnosing-a-urinary-tract-infection","fullItemName":"Diagnosing a urinary tract infection"},{"id":"57282b06-7213-5787-8603-4673c4ead4c4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"d3a08393-35d5-53dc-935a-d5e32abee30b","fullItemName":"Management","slug":"management","subChapters":[{"id":"732454b5-6086-54ad-8fe0-68d4d8c9b5f8","slug":"uti-in-children","fullItemName":"Scenario: UTI in children"},{"id":"47d251fa-94da-5df5-889b-aec47b266935","slug":"recurrent-uti-in-children","fullItemName":"Scenario: Recurrent UTI in children"}]},{"id":"fcc5959a-b3b9-5135-9a34-0567f5ec597e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"49e814b6-1bc7-5c87-91e7-ea6edc49413f","slug":"trimethoprim","fullItemName":"Trimethoprim"},{"id":"178d0dc1-f68e-5c02-8ab6-590182cdb89b","slug":"nitrofurantoin","fullItemName":"Nitrofurantoin"},{"id":"f0eecb36-6697-52c3-ba61-43722573d661","slug":"cefalexin","fullItemName":"Cefalexin"},{"id":"32a374c4-43e1-56a3-bc3a-3750191e085c","slug":"amoxicillin","fullItemName":"Amoxicillin"}]},{"id":"8b665f09-70b4-5fb0-a6c8-77c4766fc268","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1d405e7c-5e75-5615-8deb-94bb5f1d64cb","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"82284d2f-4c04-573e-861c-5f030553a063","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"27e92d92-08e0-5fd8-aa0b-a5d456171c04","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3afd108c-e35b-5034-9573-81cf33f52df5","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ce068350-baea-5cb3-9040-ab2a90e020f8","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e6c46138-9934-5c77-9727-4d36f784738d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"46eac86e-96b0-524a-ac9a-887b17be1e1c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"fcc5959a-b3b9-5135-9a34-0567f5ec597e","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"46331be4-5ea1-51d7-a8f0-56ec3d578ec5","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 0ddd1a16-54e1-4cdf-8d35-a82a01240cc0 --><h3>Contraindications and cautions</h3><!-- end field 0ddd1a16-54e1-4cdf-8d35-a82a01240cc0 -->","summary":"","htmlStringContent":"<!-- begin item 5cb5016f-2691-45a0-a40a-a82a01240589 --><!-- begin field e4e96b98-2ee3-4b6f-9725-a83501367c9c --><ul><li><strong>Do not prescribe trimethoprim to children:</strong><ul><li>With megaloblastic anaemia or other blood dyscrasias.</li></ul></li><li><strong>Prescribe trimethoprim with caution to children with:</strong><ul><li>Acute porphyria.</li><li>Hyperkalaemia, or taking medication that is known to cause hyperkalaemia.</li><li>Predisposition to folate deficiency.</li><li>Renal impairment - in children, use half normal dose after 3 days if estimated glomerular filtration rate 15-30 mL/minute/1.73 m<sup>2</sup>, use half normal dose if estimated glomerular filtration rate less than 15 mL/minute/1.73 m<sup>2</sup>, monitor plasma-trimethoprim concentration if eGFR less than 10 mL/minute/1.73 m<sup>2</sup>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">BNF 76, 2018</a>]</p><!-- end field e4e96b98-2ee3-4b6f-9725-a83501367c9c --><!-- end item 5cb5016f-2691-45a0-a40a-a82a01240589 -->","subChapters":[]},{"id":"4039d83c-f0ca-5bae-aad9-497ab31ffa6e","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 30eb873c-0b7b-49da-8c68-a82a012427bd --><h3>Adverse effects</h3><!-- end field 30eb873c-0b7b-49da-8c68-a82a012427bd -->","summary":"","htmlStringContent":"<!-- begin item de0c483a-e0fb-4791-9862-a82a012423aa --><!-- begin field 466f571c-3135-40fa-b978-a82a012427bd --><ul><li><strong>Blood disorders</strong> — leucopenia, megaloblastic anaemia, thrombocytopenia, agranulocyctosis, hyperkalaemia, methaemoglobinaemia.</li><li><strong>Gastrointestinal</strong> — diarrhoea, nausea, vomiting (common), glossitis.</li><li><strong>Nervous system</strong> — headache (common), aseptic meningitis (frequency unknown).</li><li><strong>Skin</strong> — Pruritus, and skin rashes (common).<ul><li><strong>Rarely: </strong>Photosensitivity, exfoliative dermatitis, fixed drug eruption, erythema multiforme, erythema nodusum, Stevens-Johnson Syndrome, toxic epidermal necrolysis, bullous dermatitis, purpura, angioedema.</li></ul></li><li><strong>Other adverse effects include:</strong><ul><li>Anaphylaxis.</li><li>Hyperkalaemia (very common). </li><li>Liver enzyme disturbances, cholestatic jaundice.</li><li>Myalgia.</li><li>Raised serum creatinine.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">BNF 76, 2018</a>]</p><!-- end field 466f571c-3135-40fa-b978-a82a012427bd --><!-- end item de0c483a-e0fb-4791-9862-a82a012423aa -->","subChapters":[]},{"id":"0d737a7d-c395-5331-a1fa-ab291dd898ab","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 7c1599dc-1ee7-4485-9228-a82a01244a05 --><h3>Drug interactions</h3><!-- end field 7c1599dc-1ee7-4485-9228-a82a01244a05 -->","summary":"","htmlStringContent":"<!-- begin item ed254c61-9028-45de-b1d7-a82a01243f81 --><!-- begin field c11e8ea8-2e82-435a-b1c2-a82a01244a05 --><ul><li><strong>Angiotensin-converting enzyme (ACE) inhibitors and </strong><strong>angiotensin-II receptor antagonists </strong><strong>AIIRAs</strong> — there may be an increased risk of hyperkalaemia with the concurrent use of these drugs and trimethoprim. Monitor potassium concentrations. </li><li><strong>Azathioprine and mercaptopurine </strong>—<strong> </strong>increased risk of haematological toxicity in people who have had a renal transplant. However, the combination is commonly used in practice. Monitor the full blood count routinely.</li><li><strong>Ciclosporin </strong>— serum creatinine levels may be increased. Possible increased risk of nephrotoxicity. Monitor renal function closely.</li><li><strong>Coumarins (warfarin) </strong>— the anticoagulant effect of coumarins may be potentiated. Monitor international normalised ratio (INR) and adjust dose accordingly.</li><li><strong>Digoxin</strong> — digoxin levels may be increased in the elderly if taken with trimethoprim. Monitor for digoxin adverse effects, and adjust dose accordingly.</li><li><strong>Diuretics</strong> — hyperkalaemia may be exacerbated by concomitant administration of diuretics, particularly potassium sparing diuretics and/or thiazide diuretics and eplerenone.</li><li><strong>Methotrexate (a folate antagonist) </strong>— there is an increased risk of haematologic adverse effects. Several cases of bone marrow suppression have been reported (some fatal). Full blood count should be monitored routinely.</li><li><strong>Phenytoin </strong>– phenytoin levels may be increased if taken with trimethoprim. Monitor phenytoin levels and adjust dose accordingly.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">BNF 76, 2018</a>]</p><!-- end field c11e8ea8-2e82-435a-b1c2-a82a01244a05 --><!-- end item ed254c61-9028-45de-b1d7-a82a01243f81 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}